glp-1 obesity drugs news today 2025 2024 was a record year for trials and is already poised to take over GLP-1 Trends: Access & Shortages,
Description
What the experts say The negative data was disappointing for many neurologists
J Clin Endocrinol Metab (2021) 106(3):91221
Br J Pharmacol
We examine how microbial community structure and environmental conditions influence pathogen survival, dissemination, and resistance persistence across interconnected food and agricultural systems
5 Tirzapetide (Mounjaro): 85% of study participants lost at least 5% body weight
These record sales have occurred despite limited insurance coverage in the U.S., with neither Wegovy nor Zepbound broadly covered by employer plans or Medicare
